이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

프로바이오틱 연구: 건강한 성인 대상 개방형 기능적 중재 및 종단적 평가 (PROFILE)

2026년 9월 16일 업데이트: OneCarbon

프로바이오틱 연구: 건강한 성인 대상 개방형 기능 중재 및 종단 평가

This study is a pre-post, open-label cohort study designed to investigate how a food-grade probiotic supplement affects biological measurements and wellbeing in healthy adults. Participants will take one capsule daily for either 1 month or 6 months.

During the study, participants will complete online cognitive tasks and provide blood and stool samples collected during home visits by trained staff. The samples will be analysed to explore changes in gut bacteria and other biological markers.

This study aims to understand whether the supplement is well tolerated and whether measurable biological changes occur. The study does not involve any experimental drugs or invasive procedures beyond blood sampling and stool collection, and participants will not be asked to change any current prescribed medications or treatments; with eligibility exclusions applying for recent antibiotics or immunosuppressants. The supplement is being studied for research purposes only and is not intended to diagnose, treat, or prevent disease. Participants will be invited to participate in a follow-up visit to assess long-term effects.

연구 개요

연구 유형

중재적

등록 (추정된)

180

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

예

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Aged 18 years or older at the time of providing informed consent.
  • In generally good health, with no known medical conditions that could interfere with the aims of the study or participant safety, as judged by self-report and screening questionnaire.
  • No history of significant psychiatric or neurological illness
  • Ability to complete study specific tasks, including:
  • Daily oral intake of a probiotic capsule
  • Self-collection of stool samples
  • Completion of online questionnaires and simple cognitive tasks
  • Able to read, understand, and communicate in English, in order to give informed consent and follow study instructions.
  • Access to the internet and a suitable device (e.g., smartphone, tablet, or computer) for completing online aspects of the study.

Exclusion Criteria:

  • Participants will be excluded from the study if any of the following criteria apply:
  • Use of any systemic antibiotic or systemic immunosuppressive medication within the past 8 weeks, including but not limited to:
  • β-lactam antibiotics, macrolides, tetracyclines, fluoroquinolones, aminoglycosides, glycopeptides, sulfonamides, antimycobacterial agents, systemic antifungals or antivirals
  • Use of any systemic immunosuppressants within the past 16 weeks, including, but not limited to:
  • Systemic corticosteroids, conventional immunosuppressants, biologic immunomodulators, targeted synthetic immunosuppressants, cytotoxic chemotherapy, or transplant-related immunosuppression.
  • A longer exclusion window is applied for systemic immunosuppressive therapies due to their prolonged and potentially lasting effects on immune function and gut microbial composition compared with systemic antibiotics.
  • Participants who commence systemic antibiotics or immunosuppressive therapy after enrolment will not be withdrawn from safety monitoring but will stop the supplement and will not continue the intervention phase of the study. With participant consent, data collected may still be used.
  • Major gastrointestinal disease or surgery:
  • Any history of significant gastrointestinal disease or surgery that may alter gut microbiome composition, immune function, or nutrient absorption, including but not limited to inflammatory bowel disease (Crohn's disease, ulcerative colitis, indeterminate colitis); coeliac disease or other chronic malabsorptive disorders; chronic liver, biliary, or pancreatic disease; moderate-to-severe or unstable irritable bowel syndrome; gastrointestinal malignancy; chronic gastrointestinal motility disorders; recurrent Clostridioides difficile infection; or any major gastrointestinal surgery such as bowel resection, bariatric surgery, colectomy, ileostomy or colostomy. Prior appendectomy or cholecystectomy alone is not exclusionary.
  • Current pregnancy or development of pregnancy, breastfeeding
  • Known allergy to probiotic or compounding ingredients:
  • Vitamin D3
  • Isomaltooligosaccharide
  • Yeast extract

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 기초 과학
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Short Phase Group

This group will receive supplementation for 1 month

This probiotic is a proprietary food-grade supplement that is not yet commercially available or CE-marked.

실험적: Long Phase Group

This group will receive supplementation for 6 months

This probiotic is a proprietary food-grade supplement that is not yet commercially available or CE-marked.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Changes in metagenome of stool samples
기간: From enrolment to the end of treatment at 4 or 24 weeks respectively. Optionally, a follow-up measure may be offered 24 weeks after the end of treatment.

The investigators will evaluate changes in genetic material in participant stool, representing establishment of the probiotic in the digestive tract

From enrolment to the end of treatment at 4 or 24 weeks respectively. Optionally, a follow-up measure may be offered 24 weeks after the end of treatment.

2차 결과 측정

결과 측정
측정값 설명
기간
Change in blood multiome
기간: From enrolment to the end of treatment at 4 or 24 weeks respectively. Optionally, a follow-up measure may be offered 24 weeks after the end of treatment.

This measure will evaluate change in blood proteins (plasma proteome) and blood metabolites (plasma metabolome). Both measures are quantified using mass to charge ratio.

From enrolment to the end of treatment at 4 or 24 weeks respectively. Optionally, a follow-up measure may be offered 24 weeks after the end of treatment.
Changes in cognition
기간: Assessed weekly from enrolment and to end of treatment at 4 or 24 weeks respectively.

Participants will complete a weekly online cognitive test administered via our remote platform. This generates a score relativised to each participant's performance, and does not utilise a scale.

Assessed weekly from enrolment and to end of treatment at 4 or 24 weeks respectively.
Change in daytime sleepiness
기간: Assessed at enrolment and at end of treatment at 4 or 24 weeks respectively.

Participants will complete the Epworth Sleepiness Scale (ESS), with a minimum score of 0, and a maximum score of 24. A higher score indicates worse daytime sleepiness.

Assessed at enrolment and at end of treatment at 4 or 24 weeks respectively.
Change in sleep quality
기간: Assessed at enrolment and at end of treatment at 4 or 24 weeks respectively.

Participants will complete the Pittsburgh Sleep Quality Index (PSQI) survey. This has a minimum global score of 0, and a maximum of 21. A higher score indicates worse sleep quality.

Assessed at enrolment and at end of treatment at 4 or 24 weeks respectively.
Change in self-reported wellbeing and mood
기간: Assessed at enrolment and at end of treatment at 4 or 24 weeks respectively.

Participants will fill out a questionnaire at the beginning and end of the study which will ask questions about subjective mood and wellbeing.

Assessed at enrolment and at end of treatment at 4 or 24 weeks respectively.
Adverse event monitoring
기간: Assessed from enrolment until end of treatment at 4 or 24 weeks respectively.

Participants will be expected to self-report any adverse features resulting from use of the supplement

Assessed from enrolment until end of treatment at 4 or 24 weeks respectively.

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2027년 7월 1일

기본 완료 (추정된)

2027년 7월 1일

연구 완료 (추정된)

2027년 7월 1일

연구 등록 날짜

최초 제출

2026년 2월 25일

QC 기준을 충족하는 최초 제출

2026년 3월 3일

처음 게시됨 (실제)

2026년 3월 9일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 21일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 16일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

IPD 계획 설명

All personal data collected during the study will be pseudonymised at the earliest possible stage. Each participant will be assigned a unique study ID number, which will be used on all samples, questionnaires, and datasets. A separate, password-protected file will securely store the link between participant names and study IDs. This file will be accessible only to authorised study personnel.

No identifiable personal information will be included in the research database or shared with external analysts. All electronic data will be stored on secure, encrypted servers in compliance with UK GDPR and the Data Protection Act 2018. Access will be limited to members of the research team through password-protected accounts and role-based permissions.

Hard copies of personal data will not be collected or stored. Any correspondence containing identifiable information (e.g. email addresses) will be deleted or anonymised once no longer needed.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다